From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995.
D016907:Adverse Drug Reaction Reporting Systems; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D004374:Ductus Arteriosus, Patent / Q000139:chemically induced; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D005317:Fetal Growth Retardation / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007557:Israel / Q000453:epidemiology; D007674:Kidney Diseases / Q000139:chemically induced; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D012042:Registries; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents